Huntington Bancshares Inc
Change company Symbol lookup
Select an option...
HBAN Huntington Bancshares Inc
AICAF Air China Ltd
BTZ BlackRock Credit Allocation Income Trust
SLG SL Green Realty Corp
SKT Tanger Factory Outlet Centers Inc
SJR Shaw Communications Inc
SJM J M Smucker Co
SJI South Jersey Industries Inc
SHW Sherwin-Williams Co
SHV iShares Short Treasury Bond ETF
Go

Financials : Banks | Mid Cap Value
Company profile

Huntington Bancshares Incorporated (Huntington) is a bank holding company. Through its subsidiaries, including its bank subsidiary, The Huntington National Bank (the Bank), the Company provides commercial and consumer banking services, mortgage banking services, automobile financing, recreational vehicle and marine financing, equipment leasing, investment management, trust services, brokerage services, insurance programs, and other financial products and services. Its segments include Consumer and Business Banking, Commercial Banking, Commercial Real Estate and Vehicle Finance, Regional Banking and The Huntington Private Client Group, Home Lending and Treasury/Other. The Bank offers commercial and consumer loans. Its consumer loans include automobile, home equity, residential mortgage, and recreational vehicle (RV) and marine finance loans. It offers demand deposits-noninterest-bearing, demand deposits-interest-bearing, money market deposits, and savings and other domestic deposits.

Closing Price
$13.84
Day's Change
-0.67 (-4.62%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.37
Day's Low
13.74
Volume
(Heavy Day)
Volume:
31,658,091

10-day average volume:
14,300,301
31,658,091

Innate Pharma Reports Third Quarter 2020 Financial Results and Business Update

1:00 am ET November 17, 2020 (Globe Newswire) Print

Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced its revenues and cash position for the first nine months of 2020.

"In November, we were very pleased that our lead proprietary asset, lacutamab, was awarded PRIME designation in Sezary Syndrome by the European Medicines Agency, which follows the US Fast Track designation by the FDA last year. Lacutamab is an important part of our strategy to build a focused proprietary pipeline, and these regulatory milestones further validate the unmet need in this patient population," said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. "In addition, the Phase 3 monalizumab clinical trial recently initiated by AstraZeneca is an important achievement for the Company, as it both validates our scientific approach while fortifying our cash position until the end of 2022. Collectively, these milestones are strong proof points in executing on our strategy and accelerating our efforts to deliver meaningful medicines to patients."

Third quarter 2020 and post-period events:

Lacutamab (IPH4102, anti-KIR3DL2 antibody):

Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca:

Avdoralimab in Inflammation (IPH5401, anti-C5aR antibody):

Avdoralimab in COVID-19:

Lumoxiti, a first-in-class marketed product for the treatment of relapsed or refractory hairy cell leukemia:

Financial results:

Cash, cash equivalents and financial assets of the Company amounted to EUR163.6 million as of September 30, 2020. As it is a post closing event, the $50 million milestone upcoming payment for the first patient dosed in the Interlink-1 Phase 3 study of monalizumab are not included in those figures. Financial liabilities amounted to EUR19.8 million.

For the nine-month periods ended September 30, 2019 and 2020, revenue from collaboration and licensing agreements mainly results from the spreading of the initial payments received under our agreements with AstraZeneca. Due to accounting rules and the timing of costs related to development activities under the collaboration with AstraZeneca, the recognition of this revenue can vary on a quarter by quarter each year. As a reminder, this has no impact on cash. Revenues for the first nine-months of 2020 amounted to EUR33.6 million, compared to EUR65.4 million for the same period in 2019.

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma's commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma's broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code   FR0010331421
Ticker code Euronext: IPH Nasdaq: IPHA
LEI         9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts, the Company's continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company's business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors                   Media
Innate Pharma               Innate Pharma
Tel.: +33 (0)4 30 30 30 30  Tracy Rossin (Global/US)
investors@innate-pharma.com Tel.: +1 240 801 0076
                            Tracy.Rossin@innate-pharma.com
                            ATCG Press
                            Marie Puvieux (France)
                            Tel.: +33 (0)9 81 87 46 72
                            innate-pharma@atcg-partners.com

Including short term investments (EUR15.5 million) and non-current financial instruments (EUR37.3 million). Not including the $50mn milestone payment from AstraZeneca for the first patient dosed in the Interlink-1 Phase 3 study of monalizumab.

https://ml.globenewswire.com/media/6fa6d804-b598-4693-b42f-0d6f7aa480ab/small/innatevertnoir-png.png

https://ml.globenewswire.com/media/6fa6d804-b598-4693-b42f-0d6f7aa480ab/small/innatevertnoir-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.